Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Ascidian Therapeutics CEO Michael Ehlers is leaving the venture investor that serves as his home base and will join MPM ...
The FDA has cleared PTC Therapeutics’ gene therapy for AADC deficiency, an ultra-rare disease that impacts the ...
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...
Johnson & Johnson is suing the federal government over HRSA's rejection of its proposed 340B drug discount model for Xarelto ...
Adaptimmune announced Wednesday that its experimental cell therapy based on T cell receptors shrank tumors by at least 30% in ...
Forward Health, a San Francisco-based primary care startup offering $150 monthly subscription services through ...
TRexBio secured $84 million Series B funding, led by Delos Capital with Eli Lilly and Johnson & Johnson participating, to ...
Flagship Pioneering has appointed two new CEO-partners to advise its portfolio companies and help steer its spinouts Apriori ...
GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...
A lot of Amgen's future rides on its experimental obesity medicine MariTide. At least in the minds of investors. Ahead of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback